COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies – Coronavirus Disease 2019 Sector Forecast

The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies.

Single User License: US $ 695

Purchase this Report @  https://www.marketreportsonline.com/contacts/purchase.php?name=814944

Scope of this Report-
– This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies.
– Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy this Report-
– An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.

Table of Contents
1 COVID-19 Pipeline of Small and Mid-Cap Companies
1.1 COVID-19 Pipeline of Small and Mid-Cap Companies
1. 2 Analysis of COVID-19 Pipeline by Phase and Type
1.3 Analysis of COVID-19 Pipeline by Market Cap
2 Vaccine Development by Small and Mid-Cap Companies
2.1 COVID-19 Vaccine Pipeline by Phase and Molecule Subtype
2.2 Highest Development Phase COVID-19 Vaccine Pipeline
3 Therapeutic Development by Small and Mid-Cap Companies
3.1 COVID-19 Therapeutic Pipeline by Phase and Molecule Type
3.2 COVID-19 Biologic Therapeutic Pipeline by Phase and Molecule Subtype
3.3 Highest Development Phase COVID-19 Therapeutic Pipeline
4 COVID-19 Deals
4.1 COVID-19-related Partnership Agreements with Small and Mid-Cap Companies
4.2 COVID-19-related Licensing Agreements with Small and Mid-Cap Companies
Key Findings
Appendix
6.1 Glossary
6.2 Methodology
6.3 Related Reports
6.4 About the Authors

Share This Post